The announcement landed with all the strategic logic one could ask for. Evotec has struck a research partnership with Plectonic Biotech aimed at tackling solid tumors — the category that accounts for roughly 90 percent of all cancers and the arena where the world’s largest pharmaceutical groups are currently spending most aggressively.
The collaboration combines Evotec’s BiTco platform, built around CD2 costimulation, with Plectonic’s LOGIBODY technology to generate preclinical proof-of-concept data. Cord Dohrmann, Evotec’s chief scientific officer, framed the deal as a natural extension of the company’s ambition to stay relevant in immuno-oncology beyond blood cancers.
Yet the market’s response tells a far more sobering story. The stock slipped back below its 50-day moving average on Thursday, and the shares now sit barely six percent above their 52-week low of EUR 3.14. At roughly EUR 3.35, the equity is trading closer to its floor than to any meaningful recovery zone, with a market capitalization of just under EUR 560 million.
A Sector Buying Innovation Wherever It Can Find It
The timing of the announcement was notable for reasons that have little to do with Evotec itself. The same day, HUTCHMED disclosed a licensing agreement with GSK for a KRAS-EGFR antibody targeting cancer, featuring an upfront payment of USD 110 million and a potential total value of up to USD 1.295 billion, including milestone payments of as much as USD 1.185 billion.
A day earlier, Boehringer Ingelheim had licensed the AI drug-discovery platform K Pro from Owkin — the third major pharmaceutical group to bet on external AI-powered research following AstraZeneca in May and Sanofi in June. The message from the industry is unmistakable: innovation is being acquired wherever it can be sourced, and Evotec is positioning itself as a participant in that movement rather than a bystander.
None of this, however, has translated into share price support. The stock has lost roughly 39 percent since the start of the year and approximately 43 percent over the past twelve months. The gap to the 52-week high of EUR 7.75, set in early November, now stands at 57 percent. This is no longer a correction; it is a structural re-rating.
Why Good News Keeps Falling on Deaf Ears
Financial terms for the Plectonic agreement were not disclosed — no milestone payments, no licensing structure, nothing for investors to anchor a valuation on. For a market that has grown increasingly impatient with pipeline narratives, an alliance without hard numbers reads as a statement of intent rather than a catalyst.
The broader environment compounds the problem. Yields on ten-year German government bonds climbed this week to a 15-year high of 3.35 percent, driven by Federal Reserve signals pointing to possible rate increases and rising oil prices amid the Iran conflict. In such conditions, companies still awaiting pipeline breakthroughs are punished without mercy, regardless of how promising individual announcements sound. DWS chief Stefan Hoops has warned of heightened volatility in technology and innovation segments, even as he stops short of predicting a financial crisis.
Should investors sell immediately? Or is it worth buying Evotec?
The sector-wide picture reinforces the pattern. The German chemical-pharmaceutical industry association VCI reported a 7.3 percent revenue increase for the second quarter but cautioned that the gain was “deceptive” and did not represent a genuine trend reversal, with capacity utilization at 73.2 percent still well below the long-term average of 83 percent. The tension between isolated positive signals and an overall fragile backdrop describes Evotec’s predicament almost perfectly.
A Contrast That Speaks Volumes
The recent trading action illustrates the dynamic with uncomfortable clarity. On Wednesday, the stock gained 4.3 percent to close at EUR 3.31 — a bounce one might instinctively attribute to the Plectonic news. But the shares had fallen to a fresh multi-year low the previous day, and the twelve-month decline stands at 44 percent depending on the measurement date. The rebound looks less like a fundamental reassessment and more like a technical counter-move following an oversold condition.
The lingering disappointment from recent quarterly results — an operating loss and a revenue decline against the prior-year quarter — continues to weigh on investor sentiment. Until those figures improve, even scientifically compelling collaborations are unlikely to spark a sustainable turnaround.
The contrast with peers is instructive. TScan Therapeutics in the United States is undergoing a radical restructuring, cutting around 75 percent of its workforce, pausing a Phase 3 program due to capital constraints, and refocusing entirely on in-vivo T-cell therapies. Evotec’s approach appears comparatively measured — a point in favor of the company’s underlying substance, though hardly a guarantee of share price performance.
The Question That Matters
Evotec has placed multiple collaboration announcements within a short window — the Plectonic deal following other reported partnerships — suggesting an active business development engine working to broaden the pipeline through external alliances rather than relying solely on expensive internal development. Strategically, that makes sense in a capital-scarce environment.
Whether that activity translates into hard cash remains the open question. The company remains scientifically credible and aligned with the major trends in oncology research. But restoring investor confidence will depend less on the next announcement than on whether the macroeconomic climate for growth stocks brightens — and whether the balance sheet can catch up with the pipeline’s promise. Until then, Evotec shares will continue to embody an uncomfortable coexistence: good news on the science, bad news on the chart, and no obvious bridge between the two.
Ad
Evotec Stock: Buy or Sell?! New Evotec Analysis from September 3 delivers the answer:
The latest Evotec figures speak for themselves: Urgent action needed for Evotec investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 3.
Evotec: Buy or sell? Read more here...
